NCT05552807

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

A Multicenter, Open Phase Ib Study to Evaluate the Efficacy and Safety of SCT-I10A in Combination With SCT200 or SCT200 in Combination With Paclitaxel/Docetaxel in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Sinocelltech Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is to explore the efficacy and safety of SCT200 with SCT-I10A or SCT200 combined with paclitaxel/docetaxel in the treatment of recurrent/metastatic head and neck squamous cell carcinoma.

Detailed description

This multicenter, open phase Ib study focused on evaluating the objective response response rates of SCT200 in combination with SCT-I10A or SCT200 in combination with paclitaxel/docetaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma who had previously received different treatments.

Conditions

• Head and Neck Squamous Carcinoma

Interventions

Type	Name	Description
DRUG	SCT-I10A	Administered intravenously
DRUG	SCT200	Administered intravenously
DRUG	paclitaxel	Administered intravenously
DRUG	docetaxel	Administered intravenously

Timeline

• Start date: 2022-06-15
• Primary completion: 2023-09-01
• Completion: 2023-09-01
• First posted: 2022-09-23
• Last updated: 2022-09-23

Locations

1 site across 1 country: China